Filter categories

Antibiotic Allergen Autoimmune Bacteria Cancer Research Cell/ Gene Therapy Cell Biology Chemistry Diagnostic Drug Discovery Drug Screening Imaging Immunology Oligonucleotide Materials Peptide Protein Regenerative Medicine Software Small Molecule Surgery Vaccine Virus Glycosylation (De)select all categories

• LAHR: IMPROVED GENOME EDITING ACCURACY AND EFFICIENCY

  The present invention, termed Ligation-Assisted Homologous Recombination (LAHR), represents an innovative genome editing strategy that combines the genome editing capabilities of CRISPR/Cas12a technology with the high-fidelity of a dual repair mechanism. This method significantly enhances the efficiency and precision of introducing specific nucleotide substitutions while minimizing off-target effects, offering a promising approach for gene therapy and biomedical research.
• ANTISENSE OLIGONUCLEOTIDE THERAPY FOR HUNTINGTON’S DISEASE

  Leiden University Medical Center's NeuroD research group has developed an antisense oligonucleotide (ASO) therapy for Huntington's Disease (HD), targeting the disease-causing HTT transcript. This novel therapy aims to reduce the toxicity of mutant HTT protein while preserving the vital functions of the normal protein, and has demonstrated improvement in symptoms in an HD mouse model, marking a significant advance in HD treatment.
• ANTISENSE OLIGONUCLEOTIDE THERAPY FOR D-CAA AND ALZHEIMER'S DISEASE

  Leiden University Medical Center's NeuroD research group has developed an innovative antisense oligonucleotide (ASO) therapy targeting APP gene mutations, applicable to D-CAA and Alzheimer's Disease (AD). This therapy is designed to modulate APP pre-mRNA splicing, reducing harmful amyloid-beta production.
• Service Offered: High-Throughput Profiling of Protein N-Glycosylation Employing Linkage-Specific Sialic Acid Esterfication

  The team of Professor Manfred Wuhrer at Leiden University Medical Center (LUMC), have developed a rapid, robust and linkage-specific high-throughput method for sialic acid stabilization and analysis of complex glycoprotein mixtures such as human plasma N-glycome.
• Service Offered: Cell Model of Immune Responses

  Scientists at Leiden University Medical Center (LUMC), have developed a dendritic cell culture system as a read-out of the immune response and as a replacement for animal testing.
• Tumor Associated Carbohydrate Antigens as Targets for Colorectal Cancer Immunotherapy

  The present invention relates to a novel method to identify highly specific tumor associated carbohydrate antigens (TACAs) derived from colorectal cancer (CRC) tissue.
• Immunomodulatory Capacity and Therapeutic Potential of S.mansoni-Derived Proteins in the Context of Immune Modulation, Asthma and/or Allergy

  Proteomics analysis on several fractions was performed and identified a number of unique proteins of which some were highly abundant. Identification of unique Breg-inducing molecules may form interesting treatment targets for inflammatory diseases such as asthma or allergies.
• Cytotoxicity of Synthesized EPD (EPD-S), A Natural Sesquiterpene Lacton, and its Future Clinical Efficacy

  The present invention is relating to a new anti-cancer drug, EPD-S. This drug shows on itself, as well as in combination with paclitaxel and cisplatin, strong cytotoxicity against ovarian cancer and other cancer types.
• Targeting ligand-bound (solid-phase) C1q

  We have recently developed recombinant fully human antibodies that strongly bind to C1q that is bound to its ligands (solid-phase) but does not bind to circulating C1q.
• Targeted Complement Inhibition

  We have developed strategies to target complement inhibition to specific tissues / cells to achieve local complement inhibition while leaving the systemic complement pool available to fight infections and achieve homeostasis.

• Unfortunately there are no search results.
  Clear your search